ACACB is a novel metabolism-related biomarker in the prediction of response to cetuximab therapy inmetastatic colorectal cancer
Cetuximab is one of the most valuable targeted therapy monoclonal antibodies in the treatment of metastatic colorectal cancer (CRC). However, the mechanisms affecting cetuximab resistance in CRC treatment remain unclear. Metabolism, especially fatty acid metabolism, has been reported to play an impo...
Main Authors: | , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
China Science Publishing & Media Ltd.
2022-09-01
|
Series: | Acta Biochimica et Biophysica Sinica |
Subjects: | |
Online Access: | https://www.sciengine.com/doi/10.3724/abbs.2022121 |